In mouse models, the inhibition of CCR2 leads to a reduction in IMs and macrophages in primary tumors and in the pre-metastatic liver, thereby enhancing anti-tumor immunity, reducing tumor growth, and limiting metastasis [35]. This evidence concerns the gene CCR2 and neoplasm.